Fontaine-Bellenger, France

Patrick René Angibaud

USPTO Granted Patents = 65 

 

 

Average Co-Inventor Count = 4.3

ph-index = 17

Forward Citations = 744(Granted Patents)

Forward Citations (Not Self Cited) = 523(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Issy-les-Moulineaux Cedex FR (2006)
  • Fontaine-Bellinger, FR (2013)
  • Val de Reuil, FR (2016)
  • Fontaine-Bellenger, FR (2005 - 2019)
  • Saint Pierre d'Autils, FR (2020)
  • Issy-les Moulineaux, FR (2021 - 2022)

Company Filing History:


Years Active: 2005-2022

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Menin-MLL Interaction
PI3K-Beta Inhibitors
FGFR Inhibitors
Histone Deacetylase Inhibitors
PARP Inhibitors
Quinoxaline Derivatives
Pyridine Derivatives
Indolyl Alkyl Amino Derivatives
Farnesyl Transferase Inhibitors
Kinase Modulators
Tetrahydrophenanthridinones
Aza-Bicyclohexyl Derivatives
65 patents (USPTO):Explore Patents

Title: **Patrick René Angibaud: A Pioneer in Pharmaceutical Innovations**

Introduction

Patrick René Angibaud, based in Fontaine-Bellenger, France, is a distinguished inventor known for his significant contributions in the field of pharmaceuticals. With an impressive portfolio of 65 patents, Angibaud has made remarkable advancements that address critical health issues, particularly in cancer, myelodysplastic syndrome (MDS), and diabetes.

Latest Patents

Among his latest innovations are two notable patents. The first, titled "Exo-aza spiro inhibitors of menin-MLL interaction," introduces compounds capable of inhibiting the menin/MLL protein/protein interaction. These compounds hold potential in treating various diseases, including cancer and diabetes. The second patent focuses on "Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors." This invention outlines substituted quinoxaline and pyridopyrazine derivatives that function as PI3K-beta inhibitors, offering new possibilities for pharmaceutical compositions and clinical applications.

Career Highlights

Throughout his career, Angibaud has worked with prominent companies, notably Janssen Pharmaceutica and Astex Therapeutics Limited. His work with these organizations has not only expanded his expertise but also contributed to developing groundbreaking medical solutions.

Collaborations

Collaboration has played a vital role in Angibaud's success. He has worked alongside esteemed coworkers, including Isabelle Noëlle Constance Pilatte and Bruno Roux, which has fostered an environment of innovation and creativity, leading to the development of numerous patents that drive advancements in healthcare.

Conclusion

Patrick René Angibaud stands out as a key figure in pharmaceutical innovation. His dedication to research and development has enabled significant strides in treating complex diseases. With a strong foundation of patents and collaborations, Angibaud continues to be a driving force in the quest to enhance patient outcomes and revolutionize medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…